Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Hematopoietic Stem-Cell Transplant Utilization in Relapsed/Refractory Hodgkin Lymphoma: A Population-Level Analysis of Statewide Claims Data

Hematopoietic Stem-Cell Transplant Utilization in Relapsed/Refractory Hodgkin Lymphoma: A... PURPOSEAlthough hematologic malignancies affect adults of all ages, few data exist on the real-world patterns of care for patients younger than 65 years in the United States. Understanding patterns of care from diagnosis through relapsed disease may provide insight about care across community and academic centers. We used a large statewide claims database to describe the path of Hodgkin lymphoma (HL) treatment among adults age < 65 years at diagnosis.METHODSWe defined a cohort of commercially insured patients with HL who underwent hematopoietic stem-cell transplantation (HSCT) from 2009 to 2013 in the Massachusetts All-Payer Claims Database (APCD). The primary goals of our study were to accurately identify patients and their treatment patterns who had relapsed/refractory HL and underwent HSCT. We also characterized time to treatment failure and overall survival.RESULTSA total of 7,613 patients had International Classification of Diseases, Ninth Revision, diagnostic codes for HL. From our algorithm, we identified 117 patients as part of the final cohort who underwent autologous and/or allogeneic HSCT. Median age was 39.0 years and 50.4% were female. Initial therapy was identified for 68 of the 117 patients (58.1%). Most (> 74.4%) of the identified transplants were autologous, and 19 patients (16.2%) underwent allogeneic transplant, with or without prior autologous transplant. Of the 68 patients with initial therapy data, the median time to HSCT after completion of initial treatment was 223.5 days (Q1 = 151.5, Q3 = 414.5).CONCLUSIONWe used the Massachusetts APCD to create a cohort of patients age < 65 years with relapsed/refractory HL. Our findings support the use of APCD for the large-scale analysis of patient characteristics, treatment patterns, and outcomes for young adult patients with hematologic malignancies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JCO: Clinical Cancer Informatics Wolters Kluwer Health

Hematopoietic Stem-Cell Transplant Utilization in Relapsed/Refractory Hodgkin Lymphoma: A Population-Level Analysis of Statewide Claims Data

Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/hematopoietic-stem-cell-transplant-utilization-in-relapsed-refractory-pIrBAZNLoe
Publisher
Wolters Kluwer Health
Copyright
© 2022 by American Society of Clinical Oncology
eISSN
2473-4276
DOI
10.1200/cci.21.00135
Publisher site
See Article on Publisher Site

Abstract

PURPOSEAlthough hematologic malignancies affect adults of all ages, few data exist on the real-world patterns of care for patients younger than 65 years in the United States. Understanding patterns of care from diagnosis through relapsed disease may provide insight about care across community and academic centers. We used a large statewide claims database to describe the path of Hodgkin lymphoma (HL) treatment among adults age < 65 years at diagnosis.METHODSWe defined a cohort of commercially insured patients with HL who underwent hematopoietic stem-cell transplantation (HSCT) from 2009 to 2013 in the Massachusetts All-Payer Claims Database (APCD). The primary goals of our study were to accurately identify patients and their treatment patterns who had relapsed/refractory HL and underwent HSCT. We also characterized time to treatment failure and overall survival.RESULTSA total of 7,613 patients had International Classification of Diseases, Ninth Revision, diagnostic codes for HL. From our algorithm, we identified 117 patients as part of the final cohort who underwent autologous and/or allogeneic HSCT. Median age was 39.0 years and 50.4% were female. Initial therapy was identified for 68 of the 117 patients (58.1%). Most (> 74.4%) of the identified transplants were autologous, and 19 patients (16.2%) underwent allogeneic transplant, with or without prior autologous transplant. Of the 68 patients with initial therapy data, the median time to HSCT after completion of initial treatment was 223.5 days (Q1 = 151.5, Q3 = 414.5).CONCLUSIONWe used the Massachusetts APCD to create a cohort of patients age < 65 years with relapsed/refractory HL. Our findings support the use of APCD for the large-scale analysis of patient characteristics, treatment patterns, and outcomes for young adult patients with hematologic malignancies.

Journal

JCO: Clinical Cancer Informatics – Wolters Kluwer Health

Published: May 18, 2022

References

  • Association of insurance with cancer care utilization and outcomes
    Ward, E; Halpern, M; Schrag, N
  • Participation in cancer clinical trials: Race-, sex-, and age-based disparities
    Murthy, VH; Krumholz, HM; Gross, CP
  • Using all-payer claims databases to study insurance and health care utilization dynamics
    Dworsky, M
  • All-payer claims databases—Uses and expanded prospects after Gobeille
    Freedman, JD; Green, L; Landon, BE
  • Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management
    Ansell, SM
  • Hodgkin lymphoma
    Press, OW; Kaushansky, K; Lichtman, MA; Prchal, JT
  • PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
    Ansell, SM; Lesokhin, AM; Borrello, I
  • Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma
    Younes, A; Gopal, AK; Smith, SE
  • Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial
    Younes, A; Santoro, A; Shipp, M
  • Claims-based definition of death in Japanese claims database: Validity and implications
    Ooba, N; Setoguchi, S; Ando, T
  • Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial
    Schmitz, N; Pfistner, B; Sextro, M
  • Health insurance across vulnerable ages: Patterns and disparities from adolescence to the early 30s
    Adams, SH; Newacheck, PW; Park, MJ
  • Addressing Medicaid/marketplace churn through multimarket plans: Assessing the current state of play
    Rosenbaum, S
  • Adolescent and young adult cancer care: Financial hardship and continued uncertainty
    Parsons, SK; Kumar, AJ
  • Impact of high-deductible health plans on health care utilization and costs
    Waters, TM; Chang, CF; Cecil, WT
  • Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma
    Connors, JM; Jurczak, W; Straus, DJ